Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trialElias Jabbour, Hagop M. Kantarjian, Joseph D. Khoury et al.|The Lancet Haematology|2022Cited by 242
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory <i>FLT3</i>-Mutated AMLNicholas J. Short, Farhad Ravandi, Naval Daver et al.|Journal of Clinical Oncology|2024Cited by 161
Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study.Nicholas J. Short, Elias Jabbour, Hagop M. Kantarjian et al.|Journal of Clinical Oncology|2021Cited by 29
Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaNicholas J. Short, Elias Jabbour, Hagop M. Kantarjian et al.|Blood|2021Cited by 26
Chemotherapy-Free Combination of Blinatumomab and Ponatinib in Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updates from a Phase II TrialFadi Haddad, Hagop M. Kantarjian, Elias Jabbour et al.|Blood|2023Cited by 11